132 related articles for article (PubMed ID: 20530454)
21. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
[TBL] [Abstract][Full Text] [Related]
22. Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer.
Tas F; Yildiz I; Kilic L; Ciftci R; Keskin S; Sen F
Am J Ther; 2016; 23(3):e670-9. PubMed ID: 23782755
[TBL] [Abstract][Full Text] [Related]
23. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.
Kelly K; Pan Z; Murphy J; Huffman DH; Bunn PA
Clin Cancer Res; 1997 Jul; 3(7):1117-23. PubMed ID: 9815791
[TBL] [Abstract][Full Text] [Related]
24. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer.
Ghielmini M; Pagani O; de Jong J; Pampallona S; Conti A; Maestroni G; Sessa C; Cavalli F
Br J Cancer; 1999 Jun; 80(7):1058-61. PubMed ID: 10362116
[TBL] [Abstract][Full Text] [Related]
25. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer.
Natale RB
Semin Oncol; 1996 Oct; 23(5 Suppl 12):2-6. PubMed ID: 8941402
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study.
Hirabayashi M; Endoh K; Teramachi M; Okuda M; Yamaguchi K; Fukuda K; Tokuhisa H; Kagioka H; Nakai N; Nakade M
Lung Cancer; 2004 Jun; 44(3):355-62. PubMed ID: 15140549
[TBL] [Abstract][Full Text] [Related]
27. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
Ichiki M; Kawasaki M; Takayama K; Ninomiya K; Kuba M; Iwami F; Miyazaki N; Oishi K; Takeo S; Aizawa H; Nakanishi Y
Cancer Chemother Pharmacol; 2006 Sep; 58(3):368-73. PubMed ID: 16395589
[TBL] [Abstract][Full Text] [Related]
28. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.
Tell R; Sederholm C; Klintenberg C; Franksson L; Brandén E; Hillerdal G; Lönn U; Lindén CJ; Ewers SB; Lamberg K; Mrazek E; Lödén B; Sjögren A; Linné T; Friesland S; Sirzén F
Anticancer Res; 2008; 28(5B):2851-7. PubMed ID: 19031924
[TBL] [Abstract][Full Text] [Related]
29. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy.
Yoh K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Oct; 58(1):73-9. PubMed ID: 17548127
[TBL] [Abstract][Full Text] [Related]
31. Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
Giaccone G; Huizing M; ten Bokkel Huinink W; Koolen M; Postmus P; van Kralingen K; van Zandwijk N; Vermorken J; Beijnen J; Dalesio O
Semin Oncol; 1994 Oct; 21(5 Suppl 8):34-8. PubMed ID: 7939761
[TBL] [Abstract][Full Text] [Related]
32. A phase I/II trial of combination paclitaxel and carboplatin in advanced or metastatic non-small cell lung cancer: preliminary results of an ongoing study.
Natale RB
Semin Oncol; 1995 Dec; 22(6 Suppl 15):34-7. PubMed ID: 8643968
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
[TBL] [Abstract][Full Text] [Related]
34. High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
Socinski MA; Shea TC
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-45-S12-51. PubMed ID: 9331121
[TBL] [Abstract][Full Text] [Related]
35. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
[TBL] [Abstract][Full Text] [Related]
36. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
[TBL] [Abstract][Full Text] [Related]
37. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
[TBL] [Abstract][Full Text] [Related]
38. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
39. [Safety evaluation of adjuvant chemotherapy by weekly paclitaxel combined with weekly carboplatin in patients with postoperative non-small cell lung cancer].
Hirose T; Nagao T; Kajikawa A; Sumi T; Sugimoto T; Hirose Y; Yoshida M; Kenzaki K
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1397-400. PubMed ID: 17876136
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.
Douillard JY; Peschel C; Shepherd F; Paz-Ares L; Arnold A; Davis M; Tonato M; Smylie M; Tu D; Voi M; Humphrey J; Ottaway J; Young K; Vreckem AV; Seymour L
Lung Cancer; 2004 Dec; 46(3):361-8. PubMed ID: 15541822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
